The Science of AOD-9604 Peptide: What Research Shows

What Is the AOD-9604 Peptide?

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically residues 177 to 191. It is stabilized by a tyrosine residue at the N-terminus and is studied in laboratory settings for its interactions with lipid metabolism pathways, independent of the insulin-like growth factor (IGF-1) axis.

AOD-9604 takes its name from its development designation: Anti-Obesity Drug fragment 9604. Researchers at Monash University in Australia first characterized the sequence in the late 1990s, noting that the C-terminal tail of hGH appeared to be the region most associated with lipolytic signaling.

The peptide spans 16 amino acids. Its sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a disulfide bond between the two cysteine residues at positions 7 and 14. That internal bridge gives the fragment structural rigidity compared to a fully linear peptide.

Because AOD-9604 does not bind the growth hormone receptor with the same affinity as full-length hGH, it does not produce the same downstream IGF-1 elevation. This distinction makes it a useful tool for researchers who want to study fat-cell signaling without confounding growth-promoting variables. It is strictly a research compound, not approved for human or veterinary therapeutic use.

Molecular Structure and Stability in Laboratory Conditions

AOD-9604 has a molecular weight of approximately 1817.1 Da and a disulfide bond between Cys177 and Cys191 that stabilizes its tertiary fold. Lyophilized powder form preserves this structure at -20 degrees C for extended periods, making it practical for batch-controlled laboratory workflows.

Structural integrity matters enormously when you are designing a reproducible experiment. The disulfide bridge in AOD-9604 is the peptide's most chemically sensitive feature. Reducing agents like dithiothreitol (DTT) or beta-mercaptoethanol will cleave it, so researchers must select compatible assay buffers carefully.

Mass spectrometry confirmation of molecular weight, ideally matching the theoretical 1817.1 Da within 0.1 Da, is the standard identity check. Any deviation beyond instrument tolerance suggests sequence error, oxidation, or incomplete disulfide formation during synthesis.

How AOD-9604 Interacts with Lipid Metabolism Pathways

In preclinical research models, AOD-9604 has been shown to stimulate lipolysis (the breakdown of stored fat) and inhibit lipogenesis (the formation of new fat cells) through mechanisms that appear to involve beta-3 adrenergic receptor signaling, without measurable changes to serum IGF-1 concentrations.

The current working model places beta-3 adrenergic receptor activation at the center of AOD-9604's lipolytic effect. Beta-3 receptors are expressed predominantly in brown and white adipose tissue, making them a logical target for lipid metabolism research. Activation increases cyclic AMP (cAMP) concentrations inside the fat cell, which in turn activates protein kinase A (PKA) and triggers the hormone-sensitive lipase (HSL) cascade.

What separates AOD-9604 from full-length hGH experimentally is the absence of somatogenic activity. Researchers studying pure lipolytic signaling can use AOD-9604 as a more targeted tool, because they do not need to account for IGF-1-mediated anabolic effects confounding the readout.

It is worth noting that all published mechanistic data comes from in vitro cell assays and animal models. There are no approved clinical applications as of 2026, and any laboratory using AOD-9604 should treat it strictly as a research tool subject to institutional protocols.

Reading a COA for AOD-9604: What Quality Data to Expect

A complete Certificate of Analysis for AOD-9604 should include: HPLC purity (typically reported as >98%), mass spectrometry identity confirmation, peptide content by amino acid analysis or UV absorbance, lot and batch number, manufacturing date, recommended storage conditions, and the testing laboratory's name and accreditation status.

Certificates of Analysis are not all created equal. Some suppliers provide a one-line purity number with no supporting chromatogram. That is not sufficient for rigorous research.

For AOD-9604 specifically, the HPLC trace should show a single dominant peak with no unresolved shoulders. Purity of 98% or higher by reverse-phase HPLC is a reasonable benchmark for research-grade material. Anything below 95% introduces a meaningful risk of assay interference from deletion sequences or oxidized species.

Mass spectrometry data should confirm the [M+H]+ or [M+2H]2+ ion at the correct m/z ratio for the theoretical mass. If the COA includes a deconvoluted spectrum with labeled peaks, that is a strong sign the supplier is being transparent rather than just printing a number.

Batch and lot numbers allow you to trace the compound back to a specific synthesis run. If a result looks anomalous in your experiment, being able to cross-reference the lot number against other batches is genuinely useful. Suppliers who rotate lot numbers frequently without documentation make that traceability impossible.

Handling a lyophilized peptide correctly is not complicated, but skipping steps causes real problems downstream. The most common mistake researchers make is adding solvent too quickly, which can cause localized aggregation before the peptide fully dissolves.

Room-temperature handling should be kept under 30 minutes. Peptides are not enzymes, but they are still sensitive to proteolytic contamination if transferred in non-sterile conditions. Use low-binding microcentrifuge tubes for aliquots, because standard polypropylene can adsorb small hydrophobic peptides at the concentrations typically used in cell-based assays.

The State of AOD-9604 Research in 2026

As of 2026, AOD-9604 remains an active preclinical research compound. It has no regulatory approval for therapeutic use in any jurisdiction. Published studies have examined its lipolytic properties in rodent and cell models, and ongoing research continues to probe its receptor pharmacology and metabolic signaling mechanisms.

Academic interest in AOD-9604 has remained steady since the early 2000s, with citations appearing across endocrinology, obesity research, and peptide biochemistry journals. The compound's appeal comes from its relatively clean mechanistic profile: targeted lipolytic activity without IGF-1 elevation makes it a controlled variable in metabolic pathway studies.

One area of growing interest is the comparison of AOD-9604 with other hGH-derived fragments, such as hGH fragment 176-191 (a closely related but slightly shorter sequence). Researchers studying structure-activity relationships need both fragments available at consistent purity to draw valid conclusions about which residues drive the observed activity.

Cartilage and bone research has also appeared in the literature, with some in vitro models examining AOD-9604's interactions with chondrocytes. These are exploratory studies, and the mechanistic basis is less established than the lipid metabolism work.

For researchers reviewing our complete AOD-9604 research guide, the broader context of these investigational threads shows why consistent, verified materials matter. A compound studied across multiple tissue types and receptor systems demands batch-to-batch reliability that only rigorous COA verification and third-party testing can provide.

All research use must comply with institutional review board policies, applicable national regulations, and established laboratory biosafety standards. AOD-9604 is for research use only.

Why Peptide Purity Levels Matter More Than Most Researchers Realize

In peptide research, a 2% impurity load is not trivial. At a 1 micromolar working concentration, a 98%-pure sample still delivers roughly 20 nanomolar of unknown byproducts into your assay, which is well within the range to activate off-target receptors or alter cell viability readouts.

This is a point worth dwelling on. Most researchers accept 98% purity as a gold standard and move on. But consider what 2% actually means at the assay level. If you are running a cell-based lipolysis assay at 100 nM AOD-9604, 2% of that sample is approximately 2 nM of something else. Peptide synthesis byproducts often include truncated sequences or oxidized variants that can interact with the same receptors or assay components as the target compound.

This is precisely why deletion sequences are worth scrutinizing in an HPLC chromatogram. A deletion sequence lacks one or more amino acids from the intended chain. For AOD-9604, deletion of either cysteine would prevent disulfide bond formation and produce a fragment with fundamentally different behavior. That fragment could still absorb UV light at 220 nm and appear as a minor HPLC peak, but its biological effect would be unpredictable.

Microbial contamination is a separate concern. Peptide synthesis uses organic chemistry solvents and resins that are not inherently sterile. Endotoxin testing (LAL assay) is an important additional check for any peptide being added to cell culture, since even picogram-level endotoxin can trigger inflammatory responses in macrophage-containing assay systems.

Frequently asked questions

What is AOD-9604 peptide used for in research?

AOD-9604 is used in preclinical research to study lipid metabolism, specifically lipolysis and lipogenesis. Laboratory models have examined its interactions with beta-3 adrenergic receptor signaling pathways in adipose tissue. It is not approved for any therapeutic use and is intended strictly for controlled laboratory research.

How does AOD-9604 differ from human growth hormone?

AOD-9604 is a 16-amino-acid fragment derived from the C-terminal region of human growth hormone (residues 177 to 191). Unlike full-length hGH, AOD-9604 does not significantly activate the growth hormone receptor and does not elevate IGF-1 levels, which makes it a more targeted tool for studying lipolytic signaling in isolation.

What purity level should AOD-9604 have for research use?

Research-grade AOD-9604 should have a purity of at least 98% as determined by reverse-phase HPLC. The Certificate of Analysis should include a chromatogram, mass spectrometry identity confirmation, batch number, and testing laboratory details. Purity below 95% introduces a meaningful risk of assay interference from synthesis byproducts.

Is AOD-9604 approved for human use?

No. As of 2026, AOD-9604 has no regulatory approval for therapeutic or clinical use in any jurisdiction. It is classified as a research compound and may only be used by qualified researchers in laboratory settings, in compliance with applicable regulations and institutional policies.

What should a Certificate of Analysis for AOD-9604 include?

A complete COA for AOD-9604 should include: HPLC purity percentage with a chromatogram, mass spectrometry identity confirmation at the correct molecular weight (~1817.1 Da), batch and lot number, manufacturing and testing dates, recommended storage conditions, and the name and accreditation status of the testing laboratory.

Related in this series

• The Science of AOD-9604 Peptide: What Research Shows